---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-095054"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:09:59.608371+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lexeo Q2 net loss $21.2M; positive interim gene therapy data in FA cardiomyopathy

## Summary
- Net loss of $21.2M ($0.64 per share) vs $13.4M ($8.30) year ago; R&D $16.6M, G&A $7.0M.
- Cash $175M expected to fund operations into 2027.
- LX2006 for FA cardiomyopathy showed no treatment-related serious adverse events; FDA engagement for registrational study surrogate endpoints initiated.
- Phase 1/2 trial for LX2020 (PKP2-ACM) recruiting; Cohort 1 data update on track for 2H 2024.
- Tim Van Hauwermeiren (co-founder/CEO argenx) appointed to Board in July 2024.

## SEC filing metadata
- accession: 0000950170-24-095054
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000095017024095054/0000950170-24-095054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000095017024095054/lxeo-20240812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-095054
- JSON: https://secwatch.observer/filing/0000950170-24-095054.json
- Plain text: https://secwatch.observer/filing/0000950170-24-095054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.